NGVT Ingevity Corp
Chemicals & Allied Products · NYSE · SEC CIK 1653477 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-3.7%
TTM net income YoY190.7%
TTM EPS YoY196.1%
Revenue 3-yr CAGR-12.7%
Net income 3-yr CAGR-22.2%
Margins
Gross margin42.0%
Operating margin—
Net margin5.3%
FCF margin10.8%
EBITDA margin—
Returns
ROE59.5%
ROA3.6%
ROIC (approx.)—
Asset turnover0.68x
Leverage & solvency
Liabilities / assets95.8%
Debt / equity18.18x
Current ratio1.48x
Interest coverage—
Cash quality & payout
Operating cash flow / net income3.02x
Accruals ratio-7.2%
Payout ratio—
Capex / revenue5.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.17B | $1.20B | $1.22B | $1.67B | $1.39B |
| Cost of revenue | $706.10M | $735.30M | $770.50M | $1.10B | $878.70M |
| Gross profit | $461.50M | $464.80M | $445.00M | $570.10M | $512.80M |
| R&D expense | $28.40M | $24.50M | $25.40M | $30.30M | $26.30M |
| SG&A expense | $171.20M | $157.80M | $161.80M | $198.80M | $179.30M |
| Operating income | $418.70M | $425.90M | $423.20M | $452.60M | $422.20M |
| Interest expense | $78.30M | $97.80M | $93.30M | $61.80M | $51.70M |
| Pretax income | -$142.10M | -$140.50M | $130.00M | $269.60M | $162.80M |
| Income tax | $8.20M | -$19.10M | $24.20M | $58.00M | $44.70M |
| Net income | -$167.10M | -$430.30M | -$5.40M | $211.60M | $118.10M |
| EBITDA | $525.10M | $534.20M | $546.00M | $561.40M | $532.10M |
| EPS (basic) | -4.61 | -11.85 | -0.15 | 5.54 | 2.97 |
| EPS (diluted) | -4.61 | -11.85 | -0.15 | 5.50 | 2.95 |
| Weighted avg. shares (diluted) | 36.22M | 36.32M | 36.71M | 38.47M | 40.06M |
| Balance sheet | |||||
| Cash & equivalents | $78.10M | $68.00M | $95.90M | $84.30M | $280.70M |
| Inventory | $186.00M | $195.90M | $308.80M | $335.00M | $241.20M |
| Current assets | $454.20M | $493.20M | $658.60M | $683.30M | $724.90M |
| PP&E, net | $608.10M | $642.90M | $762.20M | $798.60M | $719.70M |
| Goodwill | $4.30M | $175.20M | $527.50M | $518.50M | $442.00M |
| Intangibles | $176.10M | $278.80M | $336.10M | $404.80M | $337.60M |
| Total assets | $1.65B | $2.02B | $2.62B | $2.74B | $2.47B |
| Current liabilities | $341.30M | $264.10M | $362.90M | $303.50M | $268.90M |
| Short-term debt | $47.10M | $61.30M | $84.40M | $900,000 | $19.60M |
| Long-term debt | $1.16B | $1.34B | $1.38B | $1.47B | $1.25B |
| Total debt | $1.21B | $1.40B | $1.47B | $1.47B | $1.27B |
| Total liabilities | $1.62B | $1.83B | $1.99B | $2.04B | $1.80B |
| Shareholders' equity | $29.70M | $195.20M | $631.40M | $698.30M | $673.80M |
| Net debt | $1.13B | $1.33B | $1.37B | $1.39B | $988.90M |
| Shares outstanding | 35.49M | 36.35M | 36.23M | 37.30M | 39.27M |
| Cash flow statement | |||||
| Operating cash flow | $331.20M | $128.60M | $205.10M | $313.40M | $293.30M |
| Capital expenditure | $57.70M | $77.60M | $109.80M | $142.50M | $103.80M |
| Free cash flow | $273.50M | $51.00M | $95.30M | $170.90M | $189.50M |
| Investing cash flow | -$57.50M | -$79.50M | -$77.30M | -$551.90M | -$138.60M |
| Financing cash flow | -$252.20M | -$70.20M | -$99.90M | $48.10M | -$133.10M |
| Depreciation & amortization | $106.40M | $108.30M | $122.80M | $108.80M | $109.90M |
| Stock-based compensation | $18.30M | $11.90M | $10.60M | $16.10M | $12.30M |
| Share buybacks | $56.30M | $0 | $92.10M | $145.20M | $109.40M |
Free plan shows the latest 5 periods; Pro shows all 12 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.